These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 20670047)

  • 1. Transdermal buprenorphine in non-oncological moderate-to-severe chronic pain.
    Gatti A; Dauri M; Leonardis F; Longo G; Marinangeli F; Mammucari M; Sabato AF
    Clin Drug Investig; 2010; 30 Suppl 2():31-8. PubMed ID: 20670047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
    Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
    Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial.
    Sittl R; Griessinger N; Likar R
    Clin Ther; 2003 Jan; 25(1):150-68. PubMed ID: 12637117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study.
    Muriel C; Failde I; Micó JA; Neira M; Sánchez-Magro I
    Clin Ther; 2005 Apr; 27(4):451-62. PubMed ID: 15922818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal pain.
    Yoon DH; Bin SI; Chan SK; Chung CK; In Y; Kim H; Lichauco JJ; Mok CC; Moon YW; Ng TK; Penserga EG; Shin DA; You D; Moon H
    BMC Musculoskelet Disord; 2017 Aug; 18(1):337. PubMed ID: 28778219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 microg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12-week, randomized, open-label, controlled, parallel-group noninferiority study.
    Karlsson M; Berggren AC
    Clin Ther; 2009 Mar; 31(3):503-13. PubMed ID: 19393841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials.
    Likar R; Kayser H; Sittl R
    Clin Ther; 2006 Jun; 28(6):943-52. PubMed ID: 16860176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
    Sorge J; Sittl R
    Clin Ther; 2004 Nov; 26(11):1808-20. PubMed ID: 15639693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transdermal buprenorphine in clinical practice--a post-marketing surveillance study in 13,179 patients.
    Griessinger N; Sittl R; Likar R
    Curr Med Res Opin; 2005 Aug; 21(8):1147-56. PubMed ID: 16083522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Transdermal buprenorphine for treatment of chronic tumor and non-tumor pain].
    Likar R; Griessinger N; Sadjak A; Sittl R
    Wien Med Wochenschr; 2003; 153(13-14):317-22. PubMed ID: 12924108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short- and intermediate-term efficacy of buprenorphine TDS in chronic painful neuropathies.
    Penza P; Campanella A; Martini A; Melli G; Lombardi R; Camozzi F; Devigili G; Lauria G
    J Peripher Nerv Syst; 2008 Dec; 13(4):283-8. PubMed ID: 19192068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine in a transdermal therapeutic system--a new option.
    Böhme K
    Clin Rheumatol; 2002 Feb; 21 Suppl 1():S13-6. PubMed ID: 11954897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pain therapy in the elderly:7-day transdermal buprenorphine patch in clinical practice. Results of a non-interventional study].
    Wahle K; Krings D; Schwenke K
    MMW Fortschr Med; 2013 Mar; 155 Suppl 1():25-31. PubMed ID: 23678668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buprenorphine transdermal system for opioid therapy in patients with chronic low back pain.
    Gordon A; Rashiq S; Moulin DE; Clark AJ; Beaulieu AD; Eisenhoffer J; Piraino PS; Quigley P; Harsanyi Z; Darke AC
    Pain Res Manag; 2010; 15(3):169-78. PubMed ID: 20577660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose 7-day transdermal buprenorphine in daily clinical practice - perceptions of elderly patients with moderate non-malignant chronic pain.
    Uberall MA; Müller-Schwefe GH
    Curr Med Res Opin; 2012 Oct; 28(10):1585-95. PubMed ID: 22978772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Buprenorphine 5, 10 and 20 μg/h transdermal patch: a review of its use in the management of chronic non-malignant pain.
    Plosker GL
    Drugs; 2011 Dec; 71(18):2491-509. PubMed ID: 22141389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Post marketing surveillance study with an analgesic (transdermal buprenorphine patch) in patients with moderate to severe chronic pain].
    Tschirner M; Ritzdorf I; Brünjes R
    MMW Fortschr Med; 2008 Sep; 150 Suppl 3():142-8. PubMed ID: 19025217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buprenorphine treatment of patients with non-malignant musculoskeletal diseases.
    Balint G
    Clin Rheumatol; 2002 Feb; 21 Suppl 1():S17-8. PubMed ID: 11954898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study.
    Mercadante S; Porzio G; Ferrera P; Aielli F; Verna L; Tirelli W; Villari P; Casuccio A
    Clin Ther; 2009 Oct; 31(10):2134-8. PubMed ID: 19922884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.